

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

NCT05845723

Status	RECRUITING
Phase	Phase 2
Sponsor	Peking Union Medical College Hospital
Enrollment	81 participants

Key Eligibility Criteria

Inclusion (5)

- Understand and voluntarily sign an informed consent form prior to any study-related assessments/procedures being conducted.
- \. Male and female subjects aged 18-65 years.
- Fulfill the 2013 International Classification Criteria for Behcet's Disease (ICBD).
- Patients with aneurysmal dilatation/aneurysm of the descending aorta and/or peripheral arteries confirmed by ultrasonography and/or computed tomography angiography (CTA).
- \. Elevated acute phase reactants ESR and hs-CRP.

Exclusion (11)

- Cardiovascular manifestations that cannot be distinguished from giant cell arteritis, Burger's disease, or atherosclerotic aneurysm; infectious aneurysm;
- Other active organ involvement related to BS that requires intensified immunosuppressive treatment, including gastrointestinal ulcers, uveitis, and parenchymal neurological involvement;
- Patients with severe aneurysms requiring emergency intervention surgery; patients with elective surgery indications require the consensus between rheumatologists and vascular surgeons to determine inclusion or exclusion.
- Severe organ dysfunction, including ALT, AST, and TBIL exceeding the upper limit of normal by more than 2 times, serum creatinine ≥ 133 mmol/L, white blood cell count $< 3 \times 10^9/L$, ANC $< 2 \times 10^9/L$, hemoglobin $< 80g/L$, platelet count $< 100 \times 10^9/L$;
- Active infection such as active tuberculosis, hepatitis B or C, syphilis, chronic EBV infection, persistent or severe bacterial or viral infection;

... and 6 more (see full listing online)

Locations (1 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China